Search - tctmd.com

Displaying 761 - 780 of 860

Sort: Relevancy | Date

News Daily News

Poor Prescription Adherence After Acute MI Continues to Vex Researchers

L.A. McKeown

June 30, 2017

CANTOS: Canakinumab Cuts MI, Stroke in Post-MI Patients With Elevated CRP

News Daily News

CANTOS: Canakinumab Cuts Combo of MI, Stroke, CV Death in Post-MI Patients With Elevated CRP

Todd Neale

June 22, 2017

News Daily News

Triple Therapy Not Being Widely Used in A-fib Patients Undergoing PCI

L.A. McKeown

May 23, 2017

News Features

How Low Can You Go? Concerns Over Aggressive LDL Lowering Eased as PCSK9 Evidence Mounts

Michael O'Riordan

May 23, 2017

News Daily News

Registry Study Supports Curbing Cholesterol Screening for Young Adults Because of Low Overall Risk

Yael L. Maxwell

May 15, 2017

News Daily News

$2 Billion Annual Price Tag for FOURIER-Eligible VA Patients on PCSK9 Inhibitor

Michael O'Riordan

May 12, 2017

News Daily News

More Excess Bleeding and No Benefit With Triple Therapy After PCI, Meta-analysis Finds

Todd Neale

May 05, 2017

News Daily News

TCTMD’s Top 10 Most Popular Stories for April 2017

Shelley Wood

April 28, 2017

News Conference News EAS 2017

Perceived Financial Barriers to Healthcare Worsen Cardiovascular Outcomes Even in Countries With Universal Medical Coverage

Yael L. Maxwell

April 27, 2017

News Daily News

Thirty-Day Readmission in Acute MI Not Linked With Hospital Care or Clinical Outcomes

Michael O'Riordan

April 27, 2017

News Daily News

Choline, Common in Eggs and Liver, Raises TMAO Levels and Increases Platelet Aggregation

Michael O'Riordan

April 24, 2017

News Daily News

Long-term MI Risk Among Stable CAD Patients: Some Clues From CORONOR

Shelley Wood

April 24, 2017

News Daily News

Who Should Get a Statin? Guidelines Don’t Match Up

Michael O'Riordan

April 20, 2017

News Daily News

One in Five Acute MI Patients Drop Statins Within 2 Years

Michael O'Riordan

April 20, 2017

News

Mortality and CVD Decline in Patients With Diabetes, but Biggest Strides Seen for Nonfatal Outcomes

Michael O'Riordan

April 13, 2017

News Daily News

ACC/AHA ‘Very High Risk’ Criteria Only Modestly Predict Recurrent Events

Michael O'Riordan

April 04, 2017

News Conference News ACC 2017

High-Dose Atorvastatin Does Not Impact Cognition, but Small Changes Observed on Brain MRI

Michael O'Riordan

March 21, 2017

News Conference News ACC 2017

Going to Low LDL Levels With Evolocumab Does Not Affect Memory, Brain Function: EBBINGHAUS

Michael O'Riordan

March 19, 2017

News Conference News ACC 2017

FOURIER: Evolocumab Reduces Risk of CVD Events by 15% Compared With Placebo

Michael O'Riordan

March 17, 2017

News Daily News

Fish Oils: Yes for HF and Secondary Prevention, No for the General Population, Says AHA

Michael O'Riordan

March 15, 2017

Advertisement

Poor Prescription Adherence After Acute MI Continues to Vex Researchers

CANTOS: Canakinumab Cuts Combo of MI, Stroke, CV Death in Post-MI Patients With Elevated CRP

Triple Therapy Not Being Widely Used in A-fib Patients Undergoing PCI

How Low Can You Go? Concerns Over Aggressive LDL Lowering Eased as PCSK9 Evidence Mounts

Registry Study Supports Curbing Cholesterol Screening for Young Adults Because of Low Overall Risk

$2 Billion Annual Price Tag for FOURIER-Eligible VA Patients on PCSK9 Inhibitor

More Excess Bleeding and No Benefit With Triple Therapy After PCI, Meta-analysis Finds

TCTMD’s Top 10 Most Popular Stories for April 2017

Perceived Financial Barriers to Healthcare Worsen Cardiovascular Outcomes Even in Countries With Universal Medical Coverage

Thirty-Day Readmission in Acute MI Not Linked With Hospital Care or Clinical Outcomes

Choline, Common in Eggs and Liver, Raises TMAO Levels and Increases Platelet Aggregation

Long-term MI Risk Among Stable CAD Patients: Some Clues From CORONOR

Who Should Get a Statin? Guidelines Don’t Match Up

One in Five Acute MI Patients Drop Statins Within 2 Years

Mortality and CVD Decline in Patients With Diabetes, but Biggest Strides Seen for Nonfatal Outcomes

ACC/AHA ‘Very High Risk’ Criteria Only Modestly Predict Recurrent Events

High-Dose Atorvastatin Does Not Impact Cognition, but Small Changes Observed on Brain MRI

Going to Low LDL Levels With Evolocumab Does Not Affect Memory, Brain Function: EBBINGHAUS

FOURIER: Evolocumab Reduces Risk of CVD Events by 15% Compared With Placebo

Fish Oils: Yes for HF and Secondary Prevention, No for the General Population, Says AHA

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content